Search results for "kinetics"

showing 10 items of 2224 documents

Sex-related Differences in Disposition and Response to Phenprocoumon in Rats

1988

Abstract The pharmacokinetics and the pharmacological response to phenprocoumon have been studied in female and male inbred Lewis-Wistar rats. A significantly lower clearance was found in female than in male rats (7.9 ± 1.4 vs 24.5 ± 2.5 mL h−1 kg−1, respectively; t = 15.09, P < 0.001) as well as a lower apparent volume of distribution (288 ± 46 vs 617 ± 105 mL kg−1; t = 7.58, P < 0.001) and a longer half-life (25.5 ± 3.4 vs 17.5 ± 1.8 h; t = 5.16, P < 0.001). The binding of phenprocoumon was higher in female than in male rats (fu: 0.0096 ± 0.0008 vs 0.0124 ± 0.0007, respectively; t = 6.66, P < 0.001). The total (C) as well as the unbound concentration (Cu) neede…

Malemedicine.medical_specialtymedicine.drug_classPharmaceutical ScienceBiologyPhenprocoumonSex FactorsPharmacokineticsInternal medicineMale ratsmedicineAnimalsCumulative effectPharmacologyVolume of distributionAnticoagulantRats Inbred StrainsSex related4-HydroxycoumarinsBlood ProteinsRatsEndocrinologyPhenprocoumonFemaleProthrombinPROTHROMBIN COMPLEXProtein Bindingmedicine.drugJournal of Pharmacy and Pharmacology
researchProduct

Posterior compartment of the lower leg reconstruction with free functional rectus femoris transfer after sarcoma resection.

2009

A 72-year-old man with the third recurrence of a low-grade liposarcoma of the right lower leg came to our attention seeking limb-salvage surgery. The tumour was removed en bloc with all the superficial posterior compartment of the leg. Appropriate foot flexion was restored by means of a free-functional rectus femoris musculocutaneous flap harvested from the ipsilateral thigh. The patient was kept on a postoperative splint for 6 weeks. Three months after the operation, clinical and elecromyographic signs of reinnervation were observed. The patient was able to walk, run and climb stairs and no donor-site morbidity was observed. Thigh extension was rated M4, comparable to the contralateral thi…

Malemedicine.medical_specialtymedicine.medical_treatmentPosterior compartment of the lower leg reconstruction with free functional rectus femoris transfer after sarcoma resection.LiposarcomaThighSurgical FlapsQuadriceps MuscleMedicineHumansSurgical FlapsCompartment (pharmacokinetics)Anterior compartment of thighAgedLegMuscle Neoplasmsbusiness.industryAnatomyLiposarcomaPlastic Surgery Proceduresmedicine.diseaseLimb SalvageSurgerybody regionsmedicine.anatomical_structureSurgerySarcomaNeoplasm Recurrence LocalbusinessSplint (medicine)ReinnervationJournal of plastic, reconstructiveaesthetic surgery : JPRAS
researchProduct

Vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis in patients with peritonitis.

2011

The aim of this study was to define a two-compartments pharmacokinetic model and to estimate the pharmacokinetic parameters of IP administered vancomycin in patients with continuous ambulatory peritoneal dialysis (CAPD) associated peritonitis. Ten patients with peritoneal dialysis treatment and peritonitis were prospectively enrolled in the study. The empiric treatment is: vancomycin 2 g every 5-7 days and ceftazidime 1500 mg per exchange, once daily. Pharmacokinetic modeling and parameter calculations were carried out using the nonlinear regression. The mean peritoneal concentration 10 min after the first peritoneal exchange of vancomycin free dialysis liquid was 9.5±7.3 μg/ml, showing tha…

Malemedicine.medical_specialtymedicine.medical_treatmentUrologyPharmaceutical SciencePeritonitisPeritonitisCeftazidimePeritoneal dialysisPharmacokineticsPeritoneal Dialysis Continuous AmbulatoryVancomycinmedicineHumansDialysisAntibacterial agentAgedbusiness.industryContinuous ambulatory peritoneal dialysisMiddle Agedmedicine.diseaseSurgeryAnti-Bacterial AgentsAmbulatoryVancomycinFemalebusinessInjections Intraperitonealmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Anticoagulation with argatroban for elective percutaneous coronary intervention: population pharmacokinetics and pharmacokinetic-pharmacodynamic rela…

2010

The synthetic direct thrombin inhibitor argatroban has a rapid onset and offset of anticoagulation. However, there are no data about the pharmacokinetic-pharmacodynamic (PK-PD) relationship of argatroban in patients undergoing contemporary percutaneous coronary intervention (PCI) and no data about other coagulation parameters than activated clotting time (ACT) in this setting. In the ARG-E04-trial, 140 patients were randomly assigned to argatroban (250, 300, or 350 μg/kg as bolus before PCI, followed by 15, 20, or 25 μg/kg/min infusion) or unfractionated heparin (70-100 IU/kg bolus). A 2-compartment model with first-order elimination adequately described the pharmacokinetic profile of argat…

Malemedicine.medical_treatmentActivated clotting timeArginineArgatrobanAntithrombinsBolus (medicine)PharmacokineticsmedicineHumansPharmacology (medical)Blood CoagulationAgedPharmacologySulfonamidesModels Statisticalmedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryHeparinEndovascular ProceduresPercutaneous coronary interventionHeparinMiddle AgedClotting timeDirect thrombin inhibitorAnesthesiaPipecolic AcidsFemaleBlood Coagulation Testsbusinessmedicine.drugJournal of clinical pharmacology
researchProduct

Reconstitution of the Complement Function in C1q-Deficient (C1qa−/−) Mice with Wild-Type Bone Marrow Cells

2001

Abstract Besides Ab-independent and Ab-dependent activation of the complement classical pathway in host defense, C1q plays a key role in the processing of immune complexes and in the clearance of apoptotic cells. In humans, C1q deficiency leads to systemic lupus erythematosus-like symptoms in over 90% of the cases, thus making this defect a strong disease susceptibility factor. Similarly, C1q-deficient mice (C1qa−/−) develop systemic lupus erythematosus-like symptoms, such as autoantibodies and glomerulonephritis. We have previously provided evidence that C1q is produced by cells of the monocyte-macrophage lineage. In this study, we have tested whether transplantation of bone marrow cells w…

Malemedicine.medical_treatmentImmunologychemical and pharmacologic phenomenaHematopoietic stem cell transplantationBiologyMiceClassical complement pathwayImmune systemimmune system diseasesY ChromosomemedicineAnimalsLupus Erythematosus SystemicImmunology and AllergyTissue DistributionRNA Messengerskin and connective tissue diseasesBone Marrow TransplantationMice KnockoutLupus erythematosusComplement C1qHematopoietic Stem Cell TransplantationGlomerulonephritismedicine.diseaseMice Inbred C57BLTransplantationKineticsmedicine.anatomical_structureImmunologyFemaleBone marrowStem cellThe Journal of Immunology
researchProduct

Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resi…

2018

In vivo pharmacokinetic analysis of [Sc]Sc-PSMA-617 was used to determine the normal organ-absorbed doses that may result from therapeutic activity of [Lu]Lu-PSMA-617 and to predict the maximum permissible activity of [Lu]Lu-PSMA-617 for patients with metastatic castration-resistant prostate carcinoma. Methods Pharmacokinetics of [Sc]Sc-PSMA-617 was evaluated in 5 patients with metastatic castration-resistant prostate carcinoma using dynamic PET/CT, followed by 3 static PET/CT acquisitions and blood sample collection over 19.5 hours, as well as urine sample collection at 2 time points. Total activity measured in source organs by PET imaging, as well as counts per milliliter measured in bloo…

Malemedicine.medical_treatmentUrineLutetiumRadiation Dosageurologic and male genital diseases030218 nuclear medicine & medical imagingCastration-Resistant Prostate CarcinomaHeterocyclic Compounds 1-Ring03 medical and health sciences0302 clinical medicinePharmacokineticsIn vivoPositron Emission Tomography Computed TomographyOrganometallic CompoundsmedicineHumansRadiology Nuclear Medicine and imagingExternal beam radiotherapyNeoplasm MetastasisAgedUrinary bladderbusiness.industryRadiotherapy Planning Computer-AssistedCarcinomaRadiotherapy DosageDipeptidesGeneral MedicineProstate-Specific AntigenProstatic Neoplasms Castration-Resistantmedicine.anatomical_structure030220 oncology & carcinogenesisSample collectionBone marrowRadiopharmaceuticalsbusinessNuclear medicineScandiumClinical Nuclear Medicine
researchProduct

The role of accessory cells in polyclonal T cell activation. I. Both induction of interleukin 2 production and of interleukin 2 responsiveness by con…

1983

Recent studies from other laboratories have shown that concanavalin A (Con A) acts at two separate steps in polyclonal T cell activation: interleukin 2 (IL2) production, and induction of responsiveness to IL2. Using a combination of techniques for the depletion of accessory cells from lymph node T cells, we have investigated which of these steps, if not both, is responsible for the known requirement for accessory cells in the Con A response. It was found that with increasing T cell purification, first the ability is lost to produce sufficient levels of endogenous IL2, whereas induction of IL2 responsiveness can still take place. Further removal of accessory cells however yields a population…

Malemusculoskeletal diseasesInterleukin 2medicine.medical_specialtyComplement Activating EnzymesT-LymphocytesT cellLymphocyte CooperationImmunologyPopulationchemical and pharmacologic phenomenaLymphocyte ActivationMiceInterleukin 21immune system diseasesInternal medicineConcanavalin AmedicineAnimalsImmunology and AllergyAntigen-presenting celleducationInterleukin 3LymphokinesMice Inbred BALB Ceducation.field_of_studybiologyComplement C1qImmune SeraHistocompatibility Antigens Class IIhemic and immune systemsCell biologyKineticsstomatognathic diseasesEndocrinologymedicine.anatomical_structurePolyclonal antibodiesConcanavalin Abiology.proteinInterleukin-2FemaleLymph NodesSpleenmedicine.drugEuropean Journal of Immunology
researchProduct

Effects of Aerodynamic Drag and Drafting on Propulsive Force and Oxygen Consumption in Double Poling Cross-country Skiing

2022

Purpose To investigate the effects of aerodynamic drag and drafting on propulsive force (FPROP), drag area (CDA), oxygen cost (V˙O2), metabolic rate (E˙) and heart rate (HR) during roller skiing on a treadmill in a wind tunnel using the double poling technique. A secondary aim was to investigate the effects of wind versus no-wind test conditions on the same physiological parameters. Methods 10 subjects of each gender participated in the experiments. One pair of skiers of the same gender roller skied simultaneously in line with the air flow; the distance between the skiers was ~2.05 m. Each pair was tested as follows: I) with wind, leading; II) with wind, drafting; III) without wind. The tre…

Malenordic skiingliikeoppiPhysical Therapy Sports Therapy and RehabilitationkilpaurheiluhiihtoBiomechanical PhenomenaOxygen ConsumptionHeart RateSkiingkineticsExercise TestaerodynamiikkaHumansOrthopedics and Sports MedicineFemalepeesausair resistancephysiological responseenergiankulutus (aineenvaihdunta)hapenotto
researchProduct

Changes in performance and poling kinetics during cross-country sprint skiing competition using the double-poling technique

2013

In this study, changes in skiing performance and poling kinetics during a simulated cross-country sprint skiing competition were investigated. Twelve elite male cross-country skiers performed simulated sprint competition (4 x 1,150 m heat with 20 min recovery between the heats) using the double-poling technique. Vertical and horizontal pole forces and cycle characteristics were measured using a force plate system (20-m long) during the starting spurt, racing speed, and finishing spurt of each heat. Moreover, heat and 20-m phase velocities were determined. Vertical and horizontal pole impulses as well as mean cycle length were calculated. The velocities of heats decreased by 2.7 +/- 1.7% (p …

Malesports equipmentCross countryPolingPhysical Therapy Sports Therapy and RehabilitationAthletic PerformanceSports EquipmentCompetition (economics)Cycle timeKineticsYoung AdultSprintSkiingEconometricsHumansOrthopedics and Sports Medicineta315Cycle lengthFatigueMathematicsSports Biomechanics
researchProduct

Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DAL…

2014

The aims of this study were to describe the variability in protein binding of teicoplanin in critically ill patients as well as the number of patients achieving therapeutic target concentrations. This report is part of the multinational pharmacokinetic DALI Study. Patients were sampled on a single day, with blood samples taken both at the midpoint and the end of the dosing interval. Total and unbound teicoplanin concentrations were assayed using validated chromatographic methods. The lower therapeutic range of teicoplanin was defined as total trough concentrations from 10 to 20 mg/L and the higher range as 10-30 mg/L. Thirteen critically ill patients were available for analysis. The followi…

Malevalidityvalidation proceInternational CooperationSettore MED/41 - Anestesiologiadrug protein bindingGastroenterologylaw.inventionPlasmaStaphylococcus infectionCritically ill patientsInterquartile rangelaw[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesAntibioticsantibiotic therapyPharmacology (medical)Pharmacology & PharmacyAntibiotics; Critically ill patients; Glycopeptides; Hypoalbuminaemia; ICU; Pharmacokinetics; Adult; Aged; Anti-Bacterial Agents; Chromatography; Critical Illness; Female; Humans; International Cooperation; Male; Middle Aged; Plasma; Protein Binding; Teicoplanin; Young Adult; Drug Monitoring; Microbiology (medical); Infectious Diseases; Pharmacology (medical)Antibiotics; Critically ill patients; Glycopeptides; Hypoalbuminaemia; ICU; Pharmacokinetics; Adult; Aged; Anti-Bacterial Agents; Chromatography; Critical Illness; Female; Humans; International Cooperation; Male; Middle Aged; Plasma; Protein Binding; Teicoplanin; Young Adult; Drug Monitoringclinical articleChromatographymedicine.diagnostic_testdrug dose regimencritical illneTeicoplaninHypoalbuminaemiaMedicine (all)articleGlycopeptidesclinical trialGeneral MedicineMiddle Agedtrough time concentrationdrug protein binding variabilityIntensive care unitGlycopeptides Antibiotics Critically ill patients Pharmacokinetics Hypoalbuminaemia ICU3. Good healthAnti-Bacterial Agentsantiinfective agentdrug distributionInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitologypriority journalmulticenter study (topic)Vancomycinblood samplingFemaleCritically ill patientDrug MonitoringHumanmedicine.drugProtein BindingMicrobiology (medical)Adultmedicine.medical_specialtyhigh performance liquid chromatographyarea under the curveCritical Illnessultraviolet spectroscopymid dose concentrationchemistryGlycopeptideMicrobiologyteicoplanin adultenterococcal infectionyoung adult Adultdrug clearanceYoung AdultTherapeutic indexPharmacokineticsInternal medicineAnti-Bacterial AgentmedicineHumanssteady statePharmacokineticsDosingAgedbusiness.industrydrug half lifeAntibioticrecommended drug doseAntibiotics; Critically ill patients; Glycopeptides; Hypoalbuminaemia; ICU; Pharmacokinetics; Adult; Aged; Anti-Bacterial Agents; Chromatography; Critical Illness; Female; Humans; International Cooperation; Male; Middle Aged; Plasma; Protein Binding; Teicoplanin; Young Adult; Drug Monitoring; Microbiology (medical); Infectious Diseases; Pharmacology (medical); Medicine (all)calibrationSurgerymulticenter studyTherapeutic drug monitoringdrug blood levelICU[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacologyfree plasma drug concentrationTeicoplaninbusinessmetabolism
researchProduct